{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:47Z","timestamp":1791075167929,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"DOI":"10.1007\/s40258-026-01078-8","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:58:42Z","timestamp":1791028722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Speed over Value: Korea\u2019s Recent Overhaul in Pharmaceutical Pricing and Reimbursement"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-1354","authenticated-orcid":false,"given":"Hye-Young","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"6","key":"1078_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.healthpol.2016.03.013","volume":"120","author":"EY Bae","year":"2016","unstructured":"Bae EY, Hong JM, Kwon HY, Jang S, Lee HJ, Bae S, et al. Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy. 2016;120(6):612\u201320. https:\/\/doi.org\/10.1016\/j.healthpol.2016.03.013.","journal-title":"Health Policy"},{"issue":"4","key":"1078_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40258-017-0307-0","volume":"15","author":"HY Kwon","year":"2017","unstructured":"Kwon HY, Godman B. Drug pricing in South Korea. Appl Health Econ Health Policy. 2017;15(4):447\u201353. https:\/\/doi.org\/10.1007\/s40258-017-0307-0.","journal-title":"Appl Health Econ Health Policy"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.vhri.2018.03.009","volume":"18","author":"EY Bae","year":"2019","unstructured":"Bae EY. Role of health technology assessment in drug policies: Korea. Value Health Reg Issues. 2019;18:24\u20139. https:\/\/doi.org\/10.1016\/j.vhri.2018.03.009.","journal-title":"Value Health Reg Issues"},{"key":"1078_CR4","unstructured":"Ministry of Health and Welfare, Republic of Korea. Expanding coverage for New Drugs and Promoting Pharmaceutical Innovation\u2026 Health Insurance Drug Pricing Overhaul Approved. Press release March 26, 2026. https:\/\/www.korea.kr\/news\/policyNewsView.do?newsId=148961578 . Accessed 28 Mar 2026."},{"issue":"5","key":"1078_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.18553\/jmcp.2022.28.5.566","volume":"28","author":"SD Sullivan","year":"2022","unstructured":"Sullivan SD, Sullivan KD, Dabbous O, Garrison LP. International reference pricing of pharmaceuticals in the United States: implications for potentially curative treatments. J Manag Care Spec Pharm. 2022;28(5):566\u201372. https:\/\/doi.org\/10.18553\/jmcp.2022.28.5.566.","journal-title":"J Manag Care Spec Pharm"},{"key":"1078_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.999220","volume":"14","author":"H Kim","year":"2023","unstructured":"Kim H, Godman B, Kwon HY, Hong SH. Introduction of managed entry agreements in Korea: problem, policy, and politics. Front Pharmacol. 2023;14:999220. https:\/\/doi.org\/10.3389\/fphar.2023.999220.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1078_CR7","first-page":"1","volume":"13","author":"HY Kwon","year":"2025","unstructured":"Kwon HY. Enhancing access to medicines through the named patient approach and dedicated funding: insights from France, Scotland, and Australia. J Korean Acad Soc Adm Pharm. 2025;13(1):1\u201314.","journal-title":"J Korean Acad Soc Adm Pharm"},{"key":"1078_CR8","unstructured":"KOMAF. Income and expenditure statement for donations 2023. www.komaf12.org."},{"key":"1078_CR9","unstructured":"Health Insurance Review and Assessment Service (HIRA). Evaluation of new drugs listed from 2007 to 2025. Submitted to the National Assembly 2025"},{"issue":"8","key":"1078_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jval.2025.04.2163","volume":"28","author":"SJ Hwang","year":"2025","unstructured":"Hwang SJ, Kim N, Seo E, Kim Y, Lee TJ. Exemption system for economic evaluation data submission for pharmaceuticals in South Korea: achievements and challenges. Value Health. 2025;28(8):1185\u201394. https:\/\/doi.org\/10.1016\/j.jval.2025.04.2163.","journal-title":"Value Health"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12913-025-12207-9","volume":"25","author":"J Hong","year":"2025","unstructured":"Hong J, Bae EY, Cha S, et al. The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national HTA agencies in South Korea, England, Australia, and Canada. BMC Health Serv Res. 2025;25:74. https:\/\/doi.org\/10.1186\/s12913-025-12207-9.","journal-title":"BMC Health Serv Res"},{"key":"1078_CR12","unstructured":"Citizens\u2019 Coalition for Economic Justice, Pharmacists for a Healthy Society, Korea Alliance for Severe Diseases, Actual Efficacy of Ultra-High-Cost New Drugs and a Call for a Review of Expedited Listing, Press release, 9 February 2026."},{"key":"1078_CR13","doi-asserted-by":"publisher","unstructured":"Jones, J. Pricing in Germany\u2014key learnings for optimizing price potential after the introduction of AMNOG . In: M. Hinder, A. Schuhmacher, J. Goldhahn, D. Hartl, editors. Principles of biomedical sciences and industry. 2022. https:\/\/doi.org\/10.1002\/9783527824014.ch13.","DOI":"10.1002\/9783527824014.ch13"},{"key":"1078_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133123000117","author":"K Kleining","year":"2023","unstructured":"Kleining K, Vogler S, Zimmermann N, et al. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit. Health Econ Policy Law. 2023. https:\/\/doi.org\/10.1017\/S1744133123000117.","journal-title":"Health Econ Policy Law"},{"issue":"7","key":"1078_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10198-020-01201-Z","volume":"21","author":"A Gandjour","year":"2020","unstructured":"Gandjour A, Sch\u00fc\u00dfler S, Hammerschmidt T, Dintsios CM. Predictors of negotiated prices for new drugs in Germany. Eur J Health Econ. 2020;21(7):1049\u201357. https:\/\/doi.org\/10.1007\/s10198-020-01201-Z.","journal-title":"Eur J Health Econ"},{"key":"1078_CR16","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36."},{"key":"1078_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2022-112159","author":"V Charlton","year":"2023","unstructured":"Charlton V. All health is not equal: the use of modifiers in NICE technology appraisal. BMJ Evid Based Med. 2023. https:\/\/doi.org\/10.1136\/bmjebm-2022-112159.","journal-title":"BMJ Evid Based Med"},{"issue":"10","key":"1078_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/01410768231192476","volume":"116","author":"A Angelis","year":"2023","unstructured":"Angelis A, Aggarwal A, Miners A, Grieve R, Cairns J, Briggs A. The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep? J R Soc Med. 2023;116(10):324\u201330. https:\/\/doi.org\/10.1177\/01410768231192476.","journal-title":"J R Soc Med"},{"key":"1078_CR19","unstructured":"Medicines and Healthcare products Regulatory Agency(MHRA). Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process, Press release 17 March 2026. https:\/\/www.gov.uk\/government\/news\/patients-to-get-new-medicines-up-to-six-months-sooner-under-new-joint-mhra-nice-approval-process."},{"issue":"3","key":"1078_CR20","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jval.2012.02.004","volume":"15","author":"M Wonder","year":"2012","unstructured":"Wonder M, Backhouse ME, Sullivan SD. Australian Managed Entry Scheme: a new manageable process for the reimbursement of new medicines? Value Health. 2012;15(3):586\u201390. https:\/\/doi.org\/10.1016\/j.jval.2012.02.004.","journal-title":"Value Health"},{"issue":"1","key":"1078_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3747\/co.26.4397","volume":"26","author":"SK Andersen","year":"2019","unstructured":"Andersen SK, Penner N, Chambers A, Trudeau ME, Chan KKW, Cheung M. Conditional approval of cancer drugs in Canada: accountability and impact on public funding. Curr Oncol. 2019;26(1):100\u20135. https:\/\/doi.org\/10.3747\/co.26.4397.","journal-title":"Curr Oncol"},{"issue":"9","key":"1078_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1377\/hlthaff.2022.00177","volume":"41","author":"L Dafny","year":"2022","unstructured":"Dafny L, Ody C, Rokos T. Giving a buck or making a buck? Donations by pharmaceutical manufacturers to independent patient assistance charities. Health Aff (Millwood). 2022;41(9):1263\u201372. https:\/\/doi.org\/10.1377\/hlthaff.2022.00177.","journal-title":"Health Aff (Millwood)."},{"key":"1078_CR23","doi-asserted-by":"publisher","DOI":"10.1787\/7a7afb35-en","volume-title":"Health at a glance 2023","author":"OECD","year":"2023","unstructured":"OECD. Health at a glance 2023. Paris: OECD Publishing; 2023. https:\/\/doi.org\/10.1787\/7a7afb35-en."},{"key":"1078_CR24","unstructured":"National Assembly. The NHI Fiscal Outlook, submitted by the NHIS, September 2025."},{"key":"1078_CR25","unstructured":"National Health Insurance Service (NHIS). Top 10 widely prescribed drugs 2021\u20132024. NHIS: 2025."},{"issue":"19","key":"1078_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1377\/hlthaff.27.1.179","volume":"27","author":"BM Yang","year":"2008","unstructured":"Yang BM, Bae EY, Kim JH. Economic evaluation and pharmaceutical reimbursement reform in South Korea\u2019s National Health Insurance. Health Aff. 2008;27(19):179\u201387.","journal-title":"Health Aff"},{"issue":"13","key":"1078_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.815029","volume":"6","author":"A Incze","year":"2022","unstructured":"Incze A, Kal\u00f3 Z, Esp\u00edn J, Kiss \u00c9, Kessabi S, Garrison LP. Assessing the consequences of external reference pricing for global access to medicines and innovation: economic analysis and policy implications. Front Pharmacol. 2022;6(13):815029. https:\/\/doi.org\/10.3389\/fphar.2022.815029.","journal-title":"Front Pharmacol"},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jval.2025.06.010","volume":"28","author":"J Grueger","year":"2025","unstructured":"Grueger J, Martin K, Sullivan SD. Referencing drug prices of other countries may not sustainably lower prices in the United States: lessons from Europe. Value Health. 2025;28:1305\u20138.","journal-title":"Value Health"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01078-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01078-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:04:07Z","timestamp":1791072247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-026-01078-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":28,"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01078-8","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}